You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Alpha 1 Protease Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute-graft-versus-host Disease, Steroid Refractory Acute GVHD, Graft-versus-host-disease Trial (Glassia)

No longer available
  • Acute-graft-versus-host Disease
  • +7 more
  • (no location specified)
Sep 30, 2020

Alpha1-Antitrypsin Deficiency Trial in United States (Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human))

Recruiting
  • Alpha1-Antitrypsin Deficiency
  • Alpha-1 15%
  • Liquid Alpha1-Proteinase Inhibitor (Human)
  • Gainesville, Florida
  • +5 more
Jan 13, 2023

Eosinophilic Esophagitis Trial (Alpha-proteinase inhibitor)

Not yet recruiting
  • Eosinophilic Esophagitis
  • Alpha-proteinase inhibitor
  • (no location specified)
Aug 2, 2022

COPD (COPD), Alpha1-Antitrypsin Deficiency Trial (ARALAST NP, Another Available A1PI)

Not yet recruiting
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Alpha1-Antitrypsin Deficiency
  • ARALAST NP
  • Another Available A1PI
  • (no location specified)
Jul 18, 2022

Bronchiectasis Adult Trial in Dundee (Alpha 1-Proteinase Inhibitor 180mg/kg, Alpha 1-Proteinase Inhibitor 120mg/kg, Sodium

Not yet recruiting
  • Bronchiectasis Adult
  • Alpha 1-Proteinase Inhibitor 180mg/kg
  • +2 more
  • Dundee, United Kingdom
    NHS Tayside
Oct 12, 2022

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

HIV Disease Trial in New York (alpha-1-Proteinase Inhibitor)

Completed
Has Results
  • HIV Disease
  • alpha-1-Proteinase Inhibitor
  • New York, New York
    Cabrini Medical Center
Aug 31, 2021

Alpha1-Antitrypsin Deficiency Trial in Aomori, Hokkaido, Tokyo (Alpha-1 MP)

Completed
Has Results
  • Alpha1-Antitrypsin Deficiency
  • Alpha-1 MP
  • Aomori, Japan
  • +2 more
Mar 22, 2022

HIV-1 Infection Trial (Doravirine, Tenofovir, Lamivudine, Baseline regimen of ritonavir- or cobicistat-boosted protease

Active, not recruiting
Has Results
  • HIV-1 Infection
  • Doravirine, Tenofovir, Lamivudine
  • +4 more
  • (no location specified)
Sep 2, 2022

COVID-19 Trial in Worldwide (Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment)

Terminated
  • COVID-19
  • Liquid Alpha1-Proteinase Inhibitor (Human)
  • +2 more
  • Birmingham, Alabama
  • +19 more
Apr 12, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Alpha1-Antitrypsin Deficiency Trial in Sapporo, Tokyo (Alpha-1 MP)

Completed
Has Results
  • Alpha1-Antitrypsin Deficiency
  • Alpha-1 MP
  • Sapporo, Japan
  • +1 more
Oct 13, 2021

Acute-graft-versus-host Disease Trial in Worldwide (Alpha-1 antitrypsin (AAT), Placebo)

Recruiting
  • Acute-graft-versus-host Disease
  • Alpha-1 antitrypsin (AAT)
  • Placebo
  • Scottsdale, Arizona
  • +19 more
Sep 8, 2022

Pulmonary Emphysema in Alpha-1 PI Deficiency Trial in Worldwide (Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP)

Recruiting
  • Pulmonary Emphysema in Alpha-1 PI Deficiency
  • Alpha-1 MP
  • 0.9% Sodium Chloride for Injection, USP
  • Phoenix, Arizona
  • +50 more
Dec 7, 2022

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency Trial in Worldwide (Alpha-1 MP)

Enrolling by invitation
  • Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
  • Alpha-1 MP
  • Phoenix, Arizona
  • +24 more
Dec 7, 2022

Alpha 1-Antitrypsin Deficiency Trial in Australia, New Zealand (Alpha1-Proteinase Inhibitor)

Completed
Has Results
  • Alpha 1-Antitrypsin Deficiency
  • Alpha1-Proteinase Inhibitor
  • Adelaide, South Australia, Australia
  • +4 more
Apr 17, 2021

HIV-1-infection Trial in Kenya (Dolutegravir)

Completed
  • HIV-1-infection
  • Kiambu, Kenya
  • +3 more
Jan 26, 2022

Alpha1-antitrypsin Deficiency Trial in San Marino (ARALAST Alpha1-Proteinase Inhibitor)

Terminated
Has Results
  • Alpha1-antitrypsin Deficiency
  • ARALAST Alpha1-Proteinase Inhibitor
  • San Marino, California
    Adupa Rao, MD
May 3, 2021

Alpha 1-Antitrypsin Deficiency Trial in Australia, New Zealand (Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor, Dose

Completed
Has Results
  • Alpha 1-Antitrypsin Deficiency
  • Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor
  • Dose of 60 mg/kg alpha1-proteinase inhibitor
  • Adelaide, South Australia, Australia
  • +6 more
Apr 17, 2021

COPD, Alpha1-antitrypsin Deficiency Trial in Australia, Canada, United States (ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg,

Terminated
Has Results
  • Chronic Obstructive Pulmonary Disease
  • Alpha1-antitrypsin Deficiency
  • ARALAST NP 60 mg/kg
  • +4 more
  • Peoria, Arizona
  • +16 more
Apr 17, 2021

Human Immunodeficiency Virus Type 1 Trial in Worldwide (D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF)

Completed
Has Results
  • Human Immunodeficiency Virus Type 1
  • Phoenix, Arizona
  • +81 more
Nov 25, 2021

Advanced Solid Tumors Trial in United States (KSQ-4279, KSQ-4279 will be combined in separate cohorts, including combination

Recruiting
  • Advanced Solid Tumors
  • KSQ-4279
  • KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
  • Boston, Massachusetts
  • +4 more
Apr 5, 2022

Alpha1-antitrypsin Deficiency Trial in Canada, United States (GLASSIA)

Completed
Has Results
  • Alpha1-antitrypsin Deficiency
  • GLASSIA
  • Tucson, Arizona
  • +17 more
Sep 17, 2021

Pancreatitis, Chronic; Diabetes; Transplant Trial in Minneapolis (etanercept, Alpha 1-Antitrypsin)

Active, not recruiting
  • Pancreatitis, Chronic; Diabetes; Transplant
  • Minneapolis, Minnesota
    University of Minnesota
Aug 12, 2022

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic

Not yet recruiting
  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • (no location specified)
Sep 13, 2022